Background: The atherogenic LDL is an impor-tant generative cause for the endothelial dys-function and the configuration of the athero-sclerotic lesions. CRP is a sensitive marker of inflammation on the vascular wall,...Background: The atherogenic LDL is an impor-tant generative cause for the endothelial dys-function and the configuration of the athero-sclerotic lesions. CRP is a sensitive marker of inflammation on the vascular wall, but also seems to participate in the atheromatic process. The correlation between LDL and CRP could form valuable guidelines for the initiation of a treatment with statins for individuals with an increased risk of ischemic incidents. Objectives: The aim of the study was to investigate a pos-sible correlation between LDL and CRP in an important number of apparently healthy indi-viduals. Methods: The study material consisted of the test results of 260 male and 484 female adults with normal LDL levels who were clini-cally healthy. The correlation between the LDL and the CRP values of this group was investi-gated in this group and CRP was compared with the respective values of a group of 60 male and 204 female adults with elevated LDL levels. Re-sults: It was ascertained that there is not a sta-tistically important correlation between LDL and CRP values in all groups (men, women, total) of the population with normal LDL levels. Addi-tionally, the CRP mean values were not statisti-cally different between the individuals with normal and raised LDL. Conclusion: A number of causes are incriminated for the results. More studies are definitely needed for the confirma-tion of the results, particularly if the findings could lead to the formation of guidelines for the application of a treatment in people with normal LDL levels but increased CRP levels.展开更多
Aims: Small dense LDL (sdLDL) cholesterol is considered a cardiovascular risk. Our purpose in this study was to evaluate the efficacy of rosuvastatin in reducing sdLDL and large buoyant LDL (lbLDL-C) in hypercholester...Aims: Small dense LDL (sdLDL) cholesterol is considered a cardiovascular risk. Our purpose in this study was to evaluate the efficacy of rosuvastatin in reducing sdLDL and large buoyant LDL (lbLDL-C) in hypercholesterolemia. Methods: Fifty-six patients with a mean baseline LDL-cholesterol (LDL-C) concentration of 173.9 ± 40.5 mg/dL were treated with rosuvastatin 2.5 mg/day for 12 weeks. LDL-C, sdLDL-C, and apolipoprotein (apo) B were assessed and l lbLDL-C was calculated (LDL-C minus sdLDL-C). Results: After 12-week treatment with rosuvastatin 2.5mg, sdLDL-C and lbLDL-C were significantly reduced from 62.1 ± 23.8 mg/dL to 34.0 ± 13.4 mg/dL, p <0.001 and 112.7 ± 34.9 mg/dL to 77.2± 29.2 mg/dL, p < 0.001 respectively, and sdLDL-C/lbLDL-C ratio and apo B also decreased significantly, from 0.36 ± 0.02 to 0.32 ± 0.02, p < 0.005 and 134.2 ± 4.3 to 93.6 ± 3.5 mg/dl, p < 0.001, respectively. In diabetic subjects there was significant correlation between percent reductions in the plasma triglyceride and sdLDL-C/ lbLDL-C ratio (r = 0.58, p < 0.005), but not between the percentage decrease in plasma triglyceride and sdLDL-C. Conclusions: Treatment with rosuvastatin is associated with significant reduction in sdLDL, lbLDL and sdLDL/lbLDL ratio.展开更多
文摘Background: The atherogenic LDL is an impor-tant generative cause for the endothelial dys-function and the configuration of the athero-sclerotic lesions. CRP is a sensitive marker of inflammation on the vascular wall, but also seems to participate in the atheromatic process. The correlation between LDL and CRP could form valuable guidelines for the initiation of a treatment with statins for individuals with an increased risk of ischemic incidents. Objectives: The aim of the study was to investigate a pos-sible correlation between LDL and CRP in an important number of apparently healthy indi-viduals. Methods: The study material consisted of the test results of 260 male and 484 female adults with normal LDL levels who were clini-cally healthy. The correlation between the LDL and the CRP values of this group was investi-gated in this group and CRP was compared with the respective values of a group of 60 male and 204 female adults with elevated LDL levels. Re-sults: It was ascertained that there is not a sta-tistically important correlation between LDL and CRP values in all groups (men, women, total) of the population with normal LDL levels. Addi-tionally, the CRP mean values were not statisti-cally different between the individuals with normal and raised LDL. Conclusion: A number of causes are incriminated for the results. More studies are definitely needed for the confirma-tion of the results, particularly if the findings could lead to the formation of guidelines for the application of a treatment in people with normal LDL levels but increased CRP levels.
文摘Aims: Small dense LDL (sdLDL) cholesterol is considered a cardiovascular risk. Our purpose in this study was to evaluate the efficacy of rosuvastatin in reducing sdLDL and large buoyant LDL (lbLDL-C) in hypercholesterolemia. Methods: Fifty-six patients with a mean baseline LDL-cholesterol (LDL-C) concentration of 173.9 ± 40.5 mg/dL were treated with rosuvastatin 2.5 mg/day for 12 weeks. LDL-C, sdLDL-C, and apolipoprotein (apo) B were assessed and l lbLDL-C was calculated (LDL-C minus sdLDL-C). Results: After 12-week treatment with rosuvastatin 2.5mg, sdLDL-C and lbLDL-C were significantly reduced from 62.1 ± 23.8 mg/dL to 34.0 ± 13.4 mg/dL, p <0.001 and 112.7 ± 34.9 mg/dL to 77.2± 29.2 mg/dL, p < 0.001 respectively, and sdLDL-C/lbLDL-C ratio and apo B also decreased significantly, from 0.36 ± 0.02 to 0.32 ± 0.02, p < 0.005 and 134.2 ± 4.3 to 93.6 ± 3.5 mg/dl, p < 0.001, respectively. In diabetic subjects there was significant correlation between percent reductions in the plasma triglyceride and sdLDL-C/ lbLDL-C ratio (r = 0.58, p < 0.005), but not between the percentage decrease in plasma triglyceride and sdLDL-C. Conclusions: Treatment with rosuvastatin is associated with significant reduction in sdLDL, lbLDL and sdLDL/lbLDL ratio.
文摘目的 分析血脂指标在慢加急性肝衰竭前期(pre-ACLF)和慢加急性肝衰竭(ACLF)组间的差异,并探讨患者进展的危险因素。方法 回顾性分析西部战区总医院2012年1月-2020年12月ACLF组(n=118)和pre-ACLF组(n=44)患者的基线年龄、白蛋白、肌酐、血常规、血脂等指标。计量资料服从正态分布的两组间比较采用成组t检验;计量资料不服从正态分布的两组间比较采用Mann-Whitney U检验。计数资料两组间比较采用χ^(2)检验。通过Logistic二元回归进行多因素分析,筛选独立预测因素。使用受试者工作特征曲线(ROC曲线)比较指标的敏感度和特异度,通过约登指数计算临界值。结果 比较两组间年龄、肌酐、白蛋白、TBil、INR、ALT、AST、TG、TC、HDL、LDL、WBC和中性粒细胞计数水平的差异,发现ACLF组患者的TC[2.02(1.56~2.37) mmol/L vs 3.01(2.57~3.66)mmol/L,Z=5.411,P<0.001]、HDL[0.40(0.25~0.49)mmol/Lvs 0.62(0.47~0.75)mmol/L,Z=4.781,P<0.001]、LDL[1.52(1.22~1.84)mmol/Lvs 1.93(1.49~2.36)mmol/L,Z=3.146,P=0.002]水平显著低于pre-ACLF组,ACLF组患者的TBil[352.13(284.32~451.19)μmol/L vs 135.80(112.80~154.68)μmol/L,Z=-9.775,P<0.001]、INR[1.96(1.71~2.51)vs 1.39(1.33~1.44),Z=-9.776,P<0.001]、WBC[6.74(5.07~9.19)×10^(9)/L vs 5.04(4.13~7.09)×10^(9)/L,Z=-3.985,P<0.001]、中性粒细胞水平[4.67(3.40~7.06)×10^(9)/L vs 3.30(2.72~5.01)×10^(9)/L,Z=-3.676,P<0.001]显著高于pre-ACLF组,两组间年龄、肌酐、白蛋白、ALT、AST和TG水平无显著差异(P值均>0.05)。进一步通过Logistic回归分析发现TC(OR=0.003,95%CI:0.000~0.068)、LDL(OR=61.901,95%CI:3.354~1 142.558)、WBC(OR=3.175,95%CI:1.097~9.185)具有独立预测价值(P值均<0.05),ROC结果显示TC的AUC为0.852,LDL敏感度为0.887,TC特异度为0.840。结论 血脂指标在pre-ACLF进展到ACLF过程中下降,提示临床医师需要关注pre-ACLF阶段脂质的变化,并及时调整营养方案。